Oncopeptides AB (publ) (LON:0RN4)

Market Cap	63.53M +189.5%
Revenue (ttm)	4.93M +130.7%
Net Income	-21.15M
EPS	-0.10
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,081
Average Volume	29,674
Open	2.915
Previous Close	2.973
Day's Range	2.915 - 2.915
52-Week Range	1.335 - 6.505
Beta	-1.49
RSI	23.30
Earnings Date	Feb 19, 2026

About Oncopeptides AB

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company’s PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hyd...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 75
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RN4

Financial Performance

In 2024, Oncopeptides AB's revenue was 31.65 million, a decrease of -10.14% compared to the previous year's 35.22 million. Losses were -284.61 million, 14.2% more than in 2023.

Financial numbers in SEK